{"id":"https://openalex.org/W1995734286","doi":"https://doi.org/10.1186/1471-244x-13-94","title":"A double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50 mg/day in adult outpatients with major depressive disorder","display_name":"A double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50 mg/day in adult outpatients with major depressive disorder","alternate_titles":[],"publication_year":2013,"publication_date":"2013-03-22","ids":{"openalex":"https://openalex.org/W1995734286","doi":"https://doi.org/10.1186/1471-244x-13-94","mag":"1995734286","pmid":"https://pubmed.ncbi.nlm.nih.gov/23517291","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/3763843"},"language":"en","primary_location":{"id":"doi:10.1186/1471-244x-13-94","doi":"https://doi.org/10.1186/1471-244x-13-94","is_oa":true,"landing_page_url":"https://doi.org/10.1186/1471-244x-13-94","pdf_url":"https://bmcpsychiatry.biomedcentral.com/counter/pdf/10.1186/1471-244X-13-94","source":{"id":"https://openalex.org/S94610253","display_name":"BMC Psychiatry","issn_l":"1471-244X","issn":["1471-244X"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-d","doyens","jufo-2","ki-jl-1","medline","norway-1","oarl","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320256","host_organization_name":"BioMed Central","host_organization_lineage":["https://openalex.org/P4310320256","https://openalex.org/P4310319965"],"host_organization_lineage_names":["BioMed Central","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"BMC Psychiatry","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W1995734286"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://bmcpsychiatry.biomedcentral.com/counter/pdf/10.1186/1471-244X-13-94","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"for the Study 3362 Investigators","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I78577930","display_name":"Columbia University","ror":"https://ror.org/00hj8s172","country_code":"US","type":"education","lineage":["https://openalex.org/I78577930"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"for the Study 3362 Investigators","raw_affiliation_strings":["Columbia University, New York., USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Columbia University, New York., USA","institution_ids":["https://openalex.org/I78577930"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032136657","display_name":"Michael R. Liebowitz","orcid":"https://orcid.org/0000-0002-8990-8845","observed_orcids":["https://orcid.org/0000-0002-8990-8845"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]},{"id":"https://openalex.org/I78577930","display_name":"Columbia University","ror":"https://ror.org/00hj8s172","country_code":"US","type":"education","lineage":["https://openalex.org/I78577930"]}],"countries":["US"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Michael R Liebowitz","raw_affiliation_strings":["Columbia University, 134 East 93rd Street, Suite 201B, New York, NY 10128, USA. MRLiebowitz@yahoo.com","Pfizer Inc, Collegeville, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Columbia University, 134 East 93rd Street, Suite 201B, New York, NY 10128, USA. MRLiebowitz@yahoo.com","institution_ids":["https://openalex.org/I78577930"]},{"raw_affiliation_string":"Pfizer Inc, Collegeville, USA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042407610","display_name":"Karen A. Tourian","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Karen A Tourian","raw_affiliation_strings":["Pfizer Inc, 500 Arcola Road, Collegeville, PA, 19426, USA","Pfizer Inc, Collegeville, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Inc, 500 Arcola Road, Collegeville, PA, 19426, USA","institution_ids":["https://openalex.org/I180857899"]},{"raw_affiliation_string":"Pfizer Inc, Collegeville, USA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Eunhee Hwang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Eunhee Hwang","raw_affiliation_strings":["Pfizer Inc, 500 Arcola Road, Collegeville, PA, 19426, USA","Pfizer Inc, Collegeville, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Inc, 500 Arcola Road, Collegeville, PA, 19426, USA","institution_ids":["https://openalex.org/I180857899"]},{"raw_affiliation_string":"Pfizer Inc, Collegeville, USA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5083589117","display_name":"Linda Mele","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Linda Mele","raw_affiliation_strings":["Pfizer Inc, 500 Arcola Road, Collegeville, PA, 19426, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Inc, 500 Arcola Road, Collegeville, PA, 19426, USA","institution_ids":["https://openalex.org/I180857899"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5032136657"],"corresponding_institution_ids":["https://openalex.org/I180857899","https://openalex.org/I78577930"],"apc_list":{"value":3290,"currency":"USD","value_usd":3290},"apc_paid":{"value":3290,"currency":"USD","value_usd":3290},"fwci":3.4172,"has_fulltext":true,"cited_by_count":52,"citation_normalized_percentile":{"value":0.91759076,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":86,"max":99},"biblio":{"volume":"13","issue":"1","first_page":"94","last_page":"94"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11071","display_name":"Treatment of Major Depression","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11071","display_name":"Treatment of Major Depression","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10853","display_name":"Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes","score":0.0,"subfield":{"id":"https://openalex.org/subfields/3205","display_name":"Experimental and Cognitive Psychology"},"field":{"id":"https://openalex.org/fields/32","display_name":"Psychology"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10272","display_name":"Mental Health Treatment and Access","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/desvenlafaxine","display_name":"desvenlafaxine","score":0.9980000257492065},{"id":"https://openalex.org/keywords/major-depressive-disorder","display_name":"major depressive disorder","score":0.9959999918937683},{"id":"https://openalex.org/keywords/antidepressant-efficacy","display_name":"antidepressant efficacy","score":0.8190000057220459},{"id":"https://openalex.org/keywords/dose-comparison","display_name":"dose comparison","score":0.7279999852180481},{"id":"https://openalex.org/keywords/placebo-response","display_name":"placebo response","score":0.6060000061988831},{"id":"https://openalex.org/keywords/treatment-emergent-adverse-events","display_name":"treatment-emergent adverse events","score":0.8420000076293945},{"id":"https://openalex.org/keywords/treatment-tolerability","display_name":"treatment tolerability","score":0.6299999952316284},{"id":"https://openalex.org/keywords/minimum-effective-dose","display_name":"minimum effective dose","score":0.6019999980926514},{"id":"https://openalex.org/keywords/outpatients","display_name":"outpatients","score":0.5580000281333923}],"concepts":[{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.9126904010772705},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.8996646404266357},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5774490237236023},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.5539851188659668},{"id":"https://openalex.org/C2780051608","wikidata":"https://www.wikidata.org/wiki/Q42844","display_name":"Major depressive disorder","level":3,"score":0.537590742111206},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.46166613698005676},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.43490657210350037},{"id":"https://openalex.org/C2776466505","wikidata":"https://www.wikidata.org/wiki/Q385555","display_name":"Hamilton Rating Scale for Depression","level":4,"score":0.41670021414756775},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.4067554473876953},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.37672367691993713},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0},{"id":"https://openalex.org/C2779144063","wikidata":"https://www.wikidata.org/wiki/Q338924","display_name":"Amygdala","level":2,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000069468","descriptor_name":"Desvenlafaxine Succinate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000928","descriptor_name":"Antidepressive Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000928","descriptor_name":"Antidepressive Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000928","descriptor_name":"Antidepressive Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D003511","descriptor_name":"Cyclohexanols","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D003511","descriptor_name":"Cyclohexanols","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D003511","descriptor_name":"Cyclohexanols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D003865","descriptor_name":"Major Depressive Disorder","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011569","descriptor_name":"Psychiatric Status Rating Scales","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1186/1471-244x-13-94","doi":"https://doi.org/10.1186/1471-244x-13-94","is_oa":true,"landing_page_url":"https://doi.org/10.1186/1471-244x-13-94","pdf_url":"https://bmcpsychiatry.biomedcentral.com/counter/pdf/10.1186/1471-244X-13-94","source":{"id":"https://openalex.org/S94610253","display_name":"BMC Psychiatry","issn_l":"1471-244X","issn":["1471-244X"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-d","doyens","jufo-2","ki-jl-1","medline","norway-1","oarl","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320256","host_organization_name":"BioMed Central","host_organization_lineage":["https://openalex.org/P4310320256","https://openalex.org/P4310319965"],"host_organization_lineage_names":["BioMed Central","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"BMC Psychiatry","raw_type":"journal-article"},{"id":"pmh:oai:europepmc.org:2756349","doi":null,"is_oa":true,"landing_page_url":"http://europepmc.org/articles/PMC3763843","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"","raw_type":"Text"},{"id":"pmh:oai:pubmedcentral.nih.gov:3763843","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3763843/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"BMC Psychiatry","raw_type":"Text"},{"id":"pmid:23517291","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/23517291","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"BMC psychiatry","raw_type":"Clinical Trial, Phase III"}],"best_oa_location":{"id":"doi:10.1186/1471-244x-13-94","doi":"https://doi.org/10.1186/1471-244x-13-94","is_oa":true,"landing_page_url":"https://doi.org/10.1186/1471-244x-13-94","pdf_url":"https://bmcpsychiatry.biomedcentral.com/counter/pdf/10.1186/1471-244X-13-94","source":{"id":"https://openalex.org/S94610253","display_name":"BMC Psychiatry","issn_l":"1471-244X","issn":["1471-244X"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-d","doyens","jufo-2","ki-jl-1","medline","norway-1","oarl","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320256","host_organization_name":"BioMed Central","host_organization_lineage":["https://openalex.org/P4310320256","https://openalex.org/P4310319965"],"host_organization_lineage_names":["BioMed Central","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"BMC Psychiatry","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Randomized Controlled Trial","id":"https://openalex.org/study-designs/randomized-controlled-trial"},{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320307765","display_name":"Pfizer","ror":"https://ror.org/01xdqrp08"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W1995734286.pdf","grobid_xml":"https://content.openalex.org/works/W1995734286.grobid-xml"},"referenced_works_count":21,"referenced_works":["https://openalex.org/W1543613740","https://openalex.org/W1969712323","https://openalex.org/W2004762037","https://openalex.org/W2011850312","https://openalex.org/W2013447731","https://openalex.org/W2014790589","https://openalex.org/W2018861453","https://openalex.org/W2023681059","https://openalex.org/W2025491005","https://openalex.org/W2043410495","https://openalex.org/W2044018276","https://openalex.org/W2059641466","https://openalex.org/W2070468494","https://openalex.org/W2078627160","https://openalex.org/W2118826874","https://openalex.org/W2131823335","https://openalex.org/W2144767826","https://openalex.org/W2327775881","https://openalex.org/W3022868799","https://openalex.org/W3090293687","https://openalex.org/W3215125900"],"related_works":["https://openalex.org/W2078627160","https://openalex.org/W2327775881","https://openalex.org/W1969712323","https://openalex.org/W2418300191","https://openalex.org/W2044018276","https://openalex.org/W2144767826","https://openalex.org/W2043410495","https://openalex.org/W2059641466","https://openalex.org/W2013447731","https://openalex.org/W2055059817"],"abstract_inverted_index":{"BACKGROUND:":[0],"In":[1],"an":[2,79],"effort":[3],"to":[4,60,72,126,168,200,208],"establish":[5],"the":[6,18,31,94,107,111,159,180,238,245],"lowest":[7],"effective":[8,240],"dose":[9,241],"of":[10,23,33,100,161,177,191,205,242,247],"desvenlafaxine":[11,14,27,64,139,144,183,206,219,243],"(administered":[12],"as":[13],"succinate),":[15],"we":[16],"assessed":[17],"efficacy,":[19],"safety,":[20],"and":[21,25,45,143,175,182,185],"tolerability":[22],"10-":[24,184],"50-mg/day":[26,186],"vs":[28],"placebo":[29,62,75,149,181],"for":[30,51,244],"treatment":[32,156,162,246],"major":[34,42,248],"depressive":[35,43,249],"disorder.":[36,250],"METHODS:":[37],"Adult":[38],"outpatients":[39],"with":[40,106,148,195],"DSM-IV-defined":[41],"disorder":[44],"a":[46,70,214],"17-item":[47],"Hamilton":[48],"Rating":[49],"Scale":[50],"Depression":[52],"(HAM-D(17))":[53],"total":[54,132],"score":[55,96],"\u226520":[56],"were":[57,104,152,198],"randomly":[58],"assigned":[59],"receive":[61],"or":[63,66,164],"(10":[65],"50":[67,145,220,235],"mg/day)":[68],"after":[69],"6-":[71],"14-day":[73],"single-blind":[74],"lead-in":[76],"period":[77],"in":[78,93,129,158,172,179,213],"8-week,":[80],"phase":[81],"3,":[82],"fixed-dose":[83],"trial.":[84],"The":[85,117],"primary":[86],"efficacy":[87],"measure":[88],"was":[89,134],"change":[90],"from":[91,124,210,227],"baseline":[92,125],"HAM-D(17)":[95,131],"analyzed":[97],"using":[98,110],"analysis":[99],"covariance.":[101],"Efficacy":[102],"analyses":[103],"conducted":[105],"intent-to-treat":[108,118],"population,":[109],"last":[112],"observation":[113],"carried":[114],"forward.":[115],"RESULTS:":[116],"population":[119],"included":[120],"673":[121],"patients.":[122],"Change":[123],"final":[127],"evaluation":[128],"adjusted":[130],"scores":[133],"not":[135,223],"significantly":[136],"different":[137],"comparing":[138],"10":[140],"mg/day":[141,146],"(-9.28)":[142],"(-8.92)":[147],"(-8.42).":[150],"There":[151],"no":[153],"differences":[154],"among":[155],"groups":[157],"rates":[160,190],"response":[163],"remission.":[165],"Discontinuations":[166],"due":[167],"adverse":[169,193],"events":[170,194],"occurred":[171],"1.8%,":[173],"0.9%,":[174],"1.8%":[176],"patients":[178],"groups,":[187],"respectively.":[188],"Overall":[189],"treatment-emergent":[192],"both":[196],"doses":[197,204],"similar":[199],"placebo.":[201,211,228],"CONCLUSIONS:":[202],"Both":[203],"failed":[207],"separate":[209],"However,":[212],"companion":[215],"study":[216],"reported":[217],"separately,":[218],"mg,":[221,225],"but":[222],"25":[224],"separated":[226],"Taken":[229],"together,":[230],"these":[231],"studies":[232],"suggest":[233],"that":[234],"mg":[236],"is":[237],"minimum":[239],"CLINICALTRIALS.GOV":[251],"IDENTIFIER:":[252],"NCT00863798":[253],"http://clinicaltrials.gov/ct2/show/NCT00863798?term=00863798&rank=1.":[254]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W1995734286","counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":4},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":5},{"year":2020,"cited_by_count":4},{"year":2019,"cited_by_count":4},{"year":2018,"cited_by_count":4},{"year":2017,"cited_by_count":8},{"year":2016,"cited_by_count":5},{"year":2015,"cited_by_count":5},{"year":2014,"cited_by_count":5},{"year":2013,"cited_by_count":3}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2016-06-24T00:00:00"}
